Cerebras Systems is emerging as a formidable competitor to Nvidia in the AI market, boasting significant advancements with its Wafer-Scale Engine that claims to outperform Nvidia's GPU solutions in speed and efficiency.
Category: Finance
Post
Globalstar Shares Close Up 31% Amid Rumors of $1.5 Billion Apple Backing
Globalstar Shares Close Up 31% Amid Rumors of $1.5 Billion Apple Backing
Post
Coinbase Shares Dive 15% as Q3 Earnings Disappoint Wall Street
Coinbase Shares Dive 15% as Q3 Earnings Disappoint Wall Street
Post
Stellantis Q3 Revenue Falls 27% Amid Inventory and Pricing Challenges
Stellantis Q3 Revenue Falls 27% Amid Inventory and Pricing Challenges
Post
Tesla Short Sellers Face $4.2 Billion in Losses After Strong Q3 Performance
Tesla Short Sellers Face $4.2 Billion in Losses After Strong Q3 Performance
Post
Stock Market Today: Balancing Economic Growth and Rising Stock Valuations
Stock futures showed little movement ahead of key earnings reports from major companies, with Ford's stock dropping 6% and VF Corp surging 21%, while rising Treasury yields and economic indicators, including job openings, are being closely monitored by investors.
Post
Waaree Energies Shares Dip on BSE Debut: Price Drops to ₹2,429 from ₹2,550
Waaree Energies Shares Dip on BSE Debut: Price Drops to ₹2,429 from ₹2,550
Post
Market Update – Indian Benchmark Indices Decline Amid Persistent FII Selling
Indian benchmark indices fell sharply on Friday due to continued FII selling, with the BSE Sensex dropping 662.87 points and the NSE's Nifty50 declining by 218.60 points, while key corporate earnings and IPO debuts are set to take center stage next week.
Post
Nokia Oyj Shares Gain Momentum with Northland’s $6.50 Target Amid Positive Ratios
Nokia Oyj Shares Gain Momentum with Northland’s $6.50 Target Amid Positive Ratios
Post
MNPR Stock – Monopar Therapeutics Stock Soars 16.6% After Alexion Partnership Announcement
Monopar Therapeutics (MNPR) recently saw its stock surge over 16.6% to $5.4 following a partnership with Alexion to develop a treatment for Wilson's disease, marking significant growth with a 167.19% increase over the past year despite reporting no revenues and a net loss of $0.10 per share.
